Based on an evaluation of 10 artificial intelligence algorithms for diabetic retinopathy screening, the U.K. National Screening Committee (NSC) recommended Eyenuk Inc.’s Eyeart system as the only one ready for live clinical implementation. The system will be rolled out first in the North East London National Health Service (NHS) Diabetes Eye Screening Program (DESP).